#1 Clinical Trials Search in Europe

Sym023

Sym023 is an innovative antibody being studied in clinical trials for the treatment of advanced solid tumors and lymphomas. This article explores the ongoing research into Sym023, its potential benefits, and its role in combination therapies for patients with difficult-to-treat cancers. We’ll examine the key findings from current clinical trials and what they mean for the future of cancer treatment.

Table of Contents

What is SYM023?

SYM023, also known as Anti-TIM-3, is a new type of cancer treatment drug currently being studied in clinical trials. It belongs to a class of medications called immunotherapy drugs, which work by helping your body’s immune system fight cancer[1]. SYM023 is a recombinant, fully human antibody, which means it’s a protein designed to mimic antibodies naturally produced by the human immune system[1].

How Does SYM023 Work?

SYM023 works by targeting a protein called TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) found on certain immune cells. By binding to TIM-3, SYM023 helps to activate immune cells[1]. This activation can potentially enhance the body’s natural ability to detect and destroy cancer cells.

In simpler terms, SYM023 acts like a key that unlocks the power of your immune system, allowing it to better recognize and fight cancer cells that it might have missed before.

What Conditions Does SYM023 Treat?

SYM023 is being studied for the treatment of various types of advanced cancers, including:

  • Solid tumors: These are abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign (not cancerous) or malignant (cancerous)[1].
  • Lymphomas: These are cancers that begin in cells of the lymph system, which is part of the body’s immune system[1].
  • Metastatic cancers: This refers to cancer that has spread from where it first started to another part of the body[1][2][3].

Specifically, clinical trials are focusing on patients with advanced or metastatic solid tumors or lymphomas that have not responded to available treatments or for which no standard treatment exists[1].

Clinical Trials Involving SYM023

Several clinical trials are currently underway to study the effectiveness and safety of SYM023:

  1. SYM023 Monotherapy Study: This trial is testing SYM023 alone in patients with advanced solid tumors or lymphomas. The main goal is to determine if SYM023 is safe and tolerable, and to find the best dose for future studies[1].
  2. Combination Studies: Other trials are investigating SYM023 in combination with other immunotherapy drugs (like SYM021 and SYM022) to see if these combinations can improve treatment outcomes[2][3].

SYM023 in Combination Therapies

Researchers are exploring the potential of combining SYM023 with other immunotherapy drugs to enhance its effectiveness. Some of these combinations include:

  • SYM023 + SYM021 (Anti-PD-1): This combination aims to target two different immune checkpoints (TIM-3 and PD-1) to potentially boost the immune response against cancer[2].
  • SYM023 + SYM022 (Anti-LAG-3): This combination targets TIM-3 and another immune checkpoint called LAG-3[2].
  • SYM023 + SYM021 + Irinotecan: This triple combination adds a traditional chemotherapy drug (irinotecan) to the immunotherapy combination[3].

These combination therapies are being studied in patients with specific types of cancer, including biliary tract carcinomas (cancers of the bile ducts) and esophageal squamous cell carcinoma (a type of esophageal cancer)[3].

Potential Side Effects

As SYM023 is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are closely monitoring for any adverse events during these studies[1][2][3]. Common side effects of immunotherapy drugs can include fatigue, skin reactions, and flu-like symptoms. More serious side effects can occur if the immune system attacks healthy cells in the body.

It’s important to note that in clinical trials, doctors carefully monitor patients for any side effects and adjust treatment as necessary to ensure patient safety.

Aspect Details
Drug Name Sym023 (Anti-TIM-3)
Type Recombinant, fully human antibody
Target TIM-3 (T-cell immunoglobulin and mucin-domain containing-3)
Mechanism Binds to TIM-3 and induces activation of immune cells
Administration Intravenous (IV) infusion, typically every 2 weeks
Cancer Types Studied Advanced solid tumors, lymphomas, biliary tract carcinomas, esophageal squamous cell carcinoma
Study Phases Phase 1 and Phase 1b
Combination Therapies Studied alone and in combination with Sym021 (anti-PD-1), Sym022 (anti-LAG-3), and irinotecan
Primary Outcomes Safety, tolerability, dose-limiting toxicities, maximum tolerated dose, recommended Phase 2 dose
Secondary Outcomes Efficacy (tumor response, survival), pharmacokinetics, immunogenicity

FAQ

  • What is Sym023? Sym023 is a recombinant, fully human antibody that binds to TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) and induces activation of immune cells. It is being studied as a potential treatment for advanced solid tumors and lymphomas.
  • How is Sym023 administered to patients? Sym023 is administered through intravenous (IV) infusion, typically over a period of about 30 minutes. The dosing schedule in clinical trials is usually once every 2 weeks (Q2W).
  • What types of cancer is Sym023 being tested for? Sym023 is being evaluated in clinical trials for patients with locally advanced/unresectable or metastatic solid tumor malignancies and lymphomas that are refractory to available therapy or for which no standard therapy is available.
  • Is Sym023 being studied alone or in combination with other treatments? Sym023 is being studied both as a monotherapy and in combination with other treatments. Some trials are investigating Sym023 in combination with other antibodies like Sym021 (anti-PD-1) and Sym022 (anti-LAG-3), as well as with chemotherapy drugs like irinotecan.
  • What are the main goals of the clinical trials involving Sym023? The main goals of the clinical trials are to assess the safety and tolerability of Sym023, determine the appropriate dosing, evaluate its effectiveness in treating cancer (measured by outcomes like tumor response and survival), and understand its effects on the immune system and overall body function.

Ongoing Clinical Trials on Sym023

  • Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Hungary Italy Romania +1

Glossary

  • TIM-3: T-cell immunoglobulin and mucin-domain containing-3, a protein involved in regulating immune responses. Sym023 targets this protein to potentially enhance the immune system's ability to fight cancer.
  • Recombinant antibody: An antibody produced using genetic engineering techniques, allowing for precise design and production of antibodies with specific properties.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter, allowing the drug to circulate throughout the body quickly.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 dose (RP2D): The dose of a drug determined to be appropriate for further testing in Phase 2 clinical trials, based on safety and efficacy data from Phase 1 trials.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment by measuring tumor size changes.
  • iRECIST: Immunotherapy Response Evaluation Criteria in Solid Tumors, a modified version of RECIST designed to better assess responses to immunotherapy treatments.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Anti-drug antibody (ADA): Antibodies produced by the body in response to a therapeutic drug, which can potentially reduce the drug's effectiveness or cause side effects.

References

  1. https://clinicaltrials.gov/study/NCT03489343
  2. https://clinicaltrials.gov/study/NCT03311412
  3. https://clinicaltrials.gov/study/NCT04641871